Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
3 clinical trials · Condition
◉ Watch Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
| Record | Firm | Date |
|---|---|---|
| Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04705454) | ADC Therapeutics S.A. |
Track Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) automatically
Every clearance here is in the API, with alerts when new ones post.